<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311323</url>
  </required_header>
  <id_info>
    <org_study_id>AHP-1</org_study_id>
    <nct_id>NCT01311323</nct_id>
  </id_info>
  <brief_title>Revascularization in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) With Multivessel and/or Unprotected Left Main Coronary Disease</brief_title>
  <acronym>MILESTONE</acronym>
  <official_title>Revascularization Strategy (PCI With DES Implantation vs CABG) in Patients With Non ST Elevation Acute Coronary Syndrome With Multivessel and/or Unprotected Left Main Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Heart of Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Heart of Poland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary
      artery disease and/or with left main narrowing who present symptoms of acute ischemia. For
      such kind of patients according to current ACC/AHA guidelines CABG (surgical
      revascularization) is recommended as a treatment method. In comparison with CABG, recent
      studies have shown that PCI (percutaneous coronary intervention) is associated with a lower
      rate of periprocedural adverse events and similar long term event-free survival in patients
      with left main disease. Our latest non randomized registry and randomized LEMANS study,
      comparing LMCA (left main coronary artery) stenting with CABG confirmed above findings.
      LEMANS ACS (acute coronary syndrome) retrospective registry of patients with UPLMCA
      (unprotected LMCA) disease and non ST elevation ACS showed lower 30 day and trend toward
      lower one year mortality after PCI when compared with CABG. It should be stressed, that acute
      ischemia substantially increase the risk of CABG. In fact, there are limited data on the
      outcome of ULMCA stenting or CABG in patients with acute coronary syndromes (ACS).

      Similarly, all randomized studies comparing PCI vs CABG in multivessel disease included
      mainly patients with stable angina, small cohort of patients with unstable angina and they
      excluded patients with non ST elevation Myocardial infarction.

      In the SYNTAX study -largest PCI vs CABG trial, randomized patients were patients with low
      perioperative risk (logistic EUROSCORE &lt;5) and ACS patients routinely excluded. High
      perioperative risk patients were included only in PCI registry.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause death</measure>
    <time_frame>One year after revascularization procedure</time_frame>
    <description>The primary endpoint is a composite of all death one year after revascularization procedure: PCI or CABG. The hypothesis test is designed to show non-inferiority of PCI to CABG for the primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of MACCE</measure>
    <time_frame>peri-hospital period, one month and one year after revascularization procedure</time_frame>
    <description>MACCE is defined as: all death, myocardial infarction, stroke, or unplanned revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural and post procedural complication</measure>
    <time_frame>peri-hospital period, one month and one year after revascularization procedure</time_frame>
    <description>Procedural and post procedural complication: length of hospital stay and frequency of prolonged hospitalization ; return to work; readmissions and cause of readmissions; angina and functional status; medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall costs of treatment strategies.</measure>
    <time_frame>one year ofter revascularization procedure</time_frame>
    <description>Hospital costs and long-term cost-effectiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of stent thrombosis or graft occlusion</measure>
    <time_frame>peri-hospital period, one month and one year after revascularization procedure</time_frame>
    <description>Stent trombosis will be defined in accordance with ARC definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic complications.</measure>
    <time_frame>peri-hospital period, one month and one year after revascularization procedure</time_frame>
    <description>Hemorrhagic complications will be clasified according to TIMI scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and impact of complete revascularization</measure>
    <time_frame>one year after revascularization procedure</time_frame>
    <description>Complete revascularization will be defined on an anatomic basis and by revascularization of all significant ischemic areas.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Multi Vessel Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>PCI with DES implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary Artery Bypass Grafting.On-pump or Off-pump CABG</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>Percutaneous Coronary Intervention</description>
    <arm_group_label>PCI with DES implantation</arm_group_label>
    <other_name>•Percutaneous coronary intervention</other_name>
    <other_name>•Multivessel coronary disease</other_name>
    <other_name>•Left main narrowing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG</intervention_name>
    <description>Coronary Artery Bypass Graft</description>
    <arm_group_label>CABG</arm_group_label>
    <other_name>Multivessel coronary artery disease</other_name>
    <other_name>Coronary artery bypass graft</other_name>
    <other_name>Left Main narrowing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Coronary Syndrome without ST elevation (NSTE-ACS): Unstable Angina (Braunwald's
             class IB,IC,IIB,IIC,IIIB,IIIC) or Non ST Elevation Myocardial Infarction (NSTEMI)

          -  Two vessel disease with proximal LAD stenosis or three vessel disease

          -  Unprotected Left Main Coronary Artery (ULMCA) de novo disease with or without
             concomitant single or multivessel coronary artery disease

          -  Patient eligible both for CABG and PCI, confirmed by interventional cardiologist and
             surgeon offering similar extension of revascularisation

          -  Signed informed consent

        Exclusion Criteria:

          -  age &lt;21

          -  ST Elevation Myocardial Infarction;

          -  Stable angina;

          -  Patients in Killip IV class;

          -  Patients required immediate PCI procedure (e.g. electric instability);

          -  Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at
             least 1 year

          -  History of haemorrhagic stroke

          -  Ischemic stroke or TIA within past 6 weeks.

          -  Hematocrit &lt;30%

          -  Platelet Count &lt;100.000/mm3

          -  Chronic renal insufficiency with creatinine clearance&lt;30 ml/min/1,73m2,

          -  Concomitant structural or valve disease requiring cardiac surgery

          -  Prior PCI of left main trunk at any time prior to randomization

          -  Prior PCI of any other coronary artery lesion within 1 year prior to randomization

          -  Prior CABG at any time prior to randomization

          -  Need for any concomitant cardiac surgery other than CABG (e.g. valve surgery, aortic
             repair, etc.), or intent that if the patient will be randomized to surgery, any
             cardiac surgical procedure other than isolated CABG will be performed

          -  Patients requiring additional surgery (cardiac or non cardiac) within 1 year

          -  Pregnancy or intention to become pregnant (women of child bearing age must have a
             recent negative pregnancy test prior to randomization)

          -  Non cardiac co-morbidities with life expectancy less than 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pawel E Buszman, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Heart of Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanislaw Trznadel, MD</last_name>
    <role>Study Director</role>
    <affiliation>American Heart of Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iwona Banasiewicz-Szkrobka, MD,PhD</last_name>
    <phone>0048602457602</phone>
    <email>wilenka@wp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanislaw Trznadel, MD</last_name>
    <email>strznadel@vp.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>American Heart of Poland, Malopolska Centre for Heart and Vascular Disease</name>
      <address>
        <city>Chrzanow</city>
        <state>Malopolska</state>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iwona Banasiewicz-Szkrobka, MD, PhD</last_name>
      <phone>0048602457602</phone>
      <email>wilenka@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Iwona Banasiewicz-Szkrobka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksander Zurakowski, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland, 2-nd Department of Cardiology</name>
      <address>
        <city>Bielsko-Biala</city>
        <state>Silesia</state>
        <zip>43-316</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bogdan Gorycki, MD,PhD</last_name>
      <phone>(+48) (33) 829 08 63; (33) 810</phone>
    </contact>
    <investigator>
      <last_name>Bogdan Gorycki, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland,3-rd Depatment of Invasive Cardiology, Angiology and Electrophysiology</name>
      <address>
        <city>Dabrowa Gornicza</city>
        <state>Silesia</state>
        <zip>41-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marek Kondys, MD,PhD</last_name>
      <phone>(+48) (33) 829 08 63; (33) 810</phone>
    </contact>
    <investigator>
      <last_name>Marek Kondys, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcin Debinski, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland 1-st Department of Cardiology and Angiology</name>
      <address>
        <city>Ustron</city>
        <state>Silesia</state>
        <zip>43-450</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marek Krol, MD,PhD</last_name>
      <phone>(+48) (33) 854 58 57, (33) 854</phone>
      <email>m.krol@klinikiserca.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Krol, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silesian Centre for Heart Disease, Department of Cardiosurgery and Transplantation</name>
      <address>
        <city>Zabrze</city>
        <state>Silesia</state>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariusz Gasior, Prof</last_name>
      <phone>004832 273 26 81</phone>
    </contact>
    <investigator>
      <last_name>Marian Zembala, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariusz Gasior, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera M. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008 Feb 5;51(5):538-45. doi: 10.1016/j.jacc.2007.09.054.</citation>
    <PMID>18237682</PMID>
  </reference>
  <reference>
    <citation>Buszman PP, Bochenek A, Konkolewska M, Trela B, Kiesz RS, Wilczyński M, Cisowski M, Krejca M, Banasiewicz-Szkróbka I, Krol M, Kondys M, Wiernek S, Orlik B, Martin JL, Tendera M, Buszman PE. Early and long-term outcomes after surgical and percutaneous myocardial revascularization in patients with non-ST-elevation acute coronary syndromes and unprotected left main disease. J Invasive Cardiol. 2009 Nov;21(11):564-9.</citation>
    <PMID>19901409</PMID>
  </reference>
  <reference>
    <citation>Buszman PE, Buszman PP, Kiesz RS, Bochenek A, Trela B, Konkolewska M, Wallace-Bradley D, Wilczyński M, Banasiewicz-Szkróbka I, Peszek-Przybyla E, Krol M, Kondys M, Milewski K, Wiernek S, Debiński M, Zurakowski A, Martin JL, Tendera M. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol. 2009 Oct 13;54(16):1500-11. doi: 10.1016/j.jacc.2009.07.007. Epub 2009 Aug 21.</citation>
    <PMID>19699048</PMID>
  </reference>
  <reference>
    <citation>Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Gwon HC, Jeong MH, Jang YS, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol. 2010 Jul 6;56(2):117-24. doi: 10.1016/j.jacc.2010.04.004. Epub 2010 May 6.</citation>
    <PMID>20451344</PMID>
  </reference>
  <reference>
    <citation>Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Kim JJ, Choo SJ, Chung CH, Lee JW, Park SW, Park SJ. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol. 2010 Oct 19;56(17):1366-75. doi: 10.1016/j.jacc.2010.03.097.</citation>
    <PMID>20946993</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Pawel E. Buszman, MD, PhD, FESC, FACC, FSCAI,</name_title>
    <organization>American Heart of Poland</organization>
  </responsible_party>
  <keyword>Multivessel Coronary Artery Disease</keyword>
  <keyword>Left Main Narrowing</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Coronary Artery Bypass Grafting</keyword>
  <keyword>Drug-Eluting Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

